Cell Res:阎锡蕴团队在动脉粥样硬化机制研究中获进展

2017-04-24 佚名 生物物理研究所

动脉粥样硬化是冠心病及缺血性脑血管病发生的主要原因。随着人们生活方式的改变,尤其是高脂饮食,动脉粥样硬化的发病率显着上升,由此而导致的死亡率也逐年增加。如何预防和治疗动脉粥样硬化是一个全民关注的健康难题。众所周知,动脉粥样硬化的主要病理特征是大中动脉血管内膜下斑块形成,其中易损斑块容易破裂出血,与心脑血管事件的发生密切相关。易损斑块的形成有以下两个重要因素:一,巨噬细胞泡沫化,即斑块中的巨噬细胞大

动脉粥样硬化是冠心病及缺血性脑血管病发生的主要原因。随着人们生活方式的改变,尤其是高脂饮食,动脉粥样硬化的发病率显着上升,由此而导致的死亡率也逐年增加。如何预防和治疗动脉粥样硬化是一个全民关注的健康难题。

众所周知,动脉粥样硬化的主要病理特征是大中动脉血管内膜下斑块形成,其中易损斑块容易破裂出血,与心脑血管事件的发生密切相关。易损斑块的形成有以下两个重要因素:一,巨噬细胞泡沫化,即斑块中的巨噬细胞大量内吞脂类物质,丧失运动能力,进而大量死亡,释放蛋白酶和脂质,使斑块软化,容易破裂;二,斑块内大量新生血管形成,导致出血和血栓形成。以上因素相互促进,共同影响斑块的易损性。因此,针对以上因素的机制探索和靶向治疗,能有效预防易损斑块的形成。

阎锡蕴团队自从2003年发现肿瘤血管新靶点CD146后,先后阐明了其在血管生成、肿瘤转移和炎症中的重要作用。前期的工作已经发现在动脉粥样硬化临床标本中,CD146的表达与斑块的易损性正相关。本文首次报道CD146是促进易损斑块形成的重要因素并阐明其机制。首先,发现CD146在斑块中的巨噬细胞和血管内皮高表达;机制研究表明,巨噬细胞上的CD146一方面作为脂质内吞的共受体促进巨噬细胞吞入更多脂质,同时作为上游调控分子抑制巨噬细胞的运动能力,从而促进巨噬细胞泡沫化;另外,斑块中血管内皮细胞的CD146发挥促进斑块内血管新生的作用。因此,CD146在易损斑块的形成中发挥双重作用。在高脂诱导的动脉粥样硬化小鼠模型中,敲除巨噬细胞上CD146或者利用特异性靶向CD146的单克隆抗体AA98,可显着抑制斑块的发展并减少易损斑块的形成。因此靶向CD146既能有效阻止巨噬细胞泡沫化,还能抑制新生血管的形成,减少出血危险,从而从根本上抑制易损斑块形成。该研究有望将CD146分子作为一个动脉粥样硬化的治疗靶标,从而预防严重的心脑血管事件的发生。

生物物理所阎锡蕴为论文的通讯作者。阎锡蕴组罗永挺和段红霞、首都医科大学附属安贞医院钱怡宁为论文的共同第一作者。该工作受到国家“973”计划 、国家自然科学基金、中科院基金先导项目等的资助。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056149, encodeId=bc2c205614925, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 24 20:18:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944450, encodeId=b3761944450dc, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Jul 18 17:18:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960181, encodeId=72ad1960181c6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 23 08:18:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869922, encodeId=d7bc18699224e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 11 00:18:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190850, encodeId=6c06190850de, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Wed Apr 26 19:53:14 CST 2017, time=2017-04-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2056149, encodeId=bc2c205614925, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 24 20:18:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944450, encodeId=b3761944450dc, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Jul 18 17:18:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960181, encodeId=72ad1960181c6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 23 08:18:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869922, encodeId=d7bc18699224e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 11 00:18:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190850, encodeId=6c06190850de, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Wed Apr 26 19:53:14 CST 2017, time=2017-04-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2056149, encodeId=bc2c205614925, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 24 20:18:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944450, encodeId=b3761944450dc, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Jul 18 17:18:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960181, encodeId=72ad1960181c6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 23 08:18:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869922, encodeId=d7bc18699224e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 11 00:18:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190850, encodeId=6c06190850de, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Wed Apr 26 19:53:14 CST 2017, time=2017-04-26, status=1, ipAttribution=)]
    2017-11-23 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=2056149, encodeId=bc2c205614925, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 24 20:18:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944450, encodeId=b3761944450dc, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Jul 18 17:18:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960181, encodeId=72ad1960181c6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 23 08:18:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869922, encodeId=d7bc18699224e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 11 00:18:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190850, encodeId=6c06190850de, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Wed Apr 26 19:53:14 CST 2017, time=2017-04-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2056149, encodeId=bc2c205614925, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 24 20:18:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944450, encodeId=b3761944450dc, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Jul 18 17:18:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960181, encodeId=72ad1960181c6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 23 08:18:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869922, encodeId=d7bc18699224e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 11 00:18:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190850, encodeId=6c06190850de, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Wed Apr 26 19:53:14 CST 2017, time=2017-04-26, status=1, ipAttribution=)]
    2017-04-26 cuiyejia

    学习了,谢谢分享

    0

相关资讯

Diabetes:磺脲类受体遗传变异、2型糖尿病和冠心病!

这些结果表明,尽管已知与体重增加相关,长期磺脲类药物治疗可降低冠心病的风险。

Lancet Diabetes Endo:载脂蛋白A亚型、脂蛋白A浓度和冠状动脉疾病

脂蛋白A异构体减小以及脂蛋白A浓度增加为独立的冠心病危险因素,降低脂蛋白A浓度可有效降低载脂蛋白A小亚型个体的冠心病风险

CIRC RES:社会融合与女性冠心病风险降低有啥关系!

由此可见,社会融合与女性CHD的发病率之间呈负相关,但在很大程度上可以通过生活方式/行为途径来解释。

Oncotarget:中高危冠心病患者或需强化他汀治疗

冠状动脉内脂质斑块不稳定,就如为将来心血管不良事件的发生埋下了“炸弹”。近期哈尔滨医科大学附属第二医院于波等通过应用光学相干断层扫描术(OCT),发现不同弗明汉心脏风险评分的冠心病患者在服用他汀后,均可通过稳定脂质斑块而获益,其中对心血管事件发生后1年内的中高危患者尤为显着。研究显示,他汀可明显降低密度脂蛋白胆固醇(LDL-C)、脂质指数以及高敏C反应蛋白(图1)。LDL-C在服药半年后降低在约7

从上腹痛患者的心电图 您能看出什么端倪?

【一般情况】女,73岁,退休,汉族。【主诉】反复上腹痛2年,加重10天。【病史摘要】患者2年前常无明显诱因下出现上腹部疼痛,位于剑突下,呈烧灼样,持续数十分钟,休息后好转,未重视。10天前患者无明显诱因下出现上腹部烧灼样痛,持续1~2小时不等,夜间平躺后明显,发作时伴有心悸、肩部不适、咽喉烧灼感,恶心、欲吐,曾呕吐胃内容物数次,每天发作数次,患者未重视。5小时前患者自觉上述症状加重,休息后无缓解来

The Anatomical Record:超声监测桡动脉——心脏病评估的新方法!

与传统的种族,年龄,性别和代谢特征的危险因素相比,动脉粥样硬化(通常被称为动脉硬化)长期以来被认为是冠状动脉疾病的强指标。与影响许多人的其他疾病不同,动脉粥样硬化目前没有简单的诊断或监测治疗反应的方法。